Steven Hirschfeld

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7481354/publications.pdf

Version: 2024-02-01

70 papers

2,912 citations

257357 24 h-index 53 g-index

73 all docs

73 docs citations

times ranked

73

4055 citing authors

| # | Article | IF | Citations |
|----|--|-----|-----------|
| 1 | Measuring Therapeutic Response in Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group Report. Biology of Blood and Marrow Transplantation, 2006, 12, 252-266. | 2.0 | 445 |
| 2 | H-2RIIBP, a member of the nuclear hormone receptor superfamily that binds to both the regulatory element of major histocompatibility class I genes and the estrogen response element Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 8289-8293. | 3.3 | 298 |
| 3 | Regulatory Approvals of Pediatric Oncology Drugs: Previous Experience and New Initiatives. Journal of Clinical Oncology, 2003, 21, 1066-1073. | 0.8 | 205 |
| 4 | National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group Report. Biology of Blood and Marrow Transplantation, 2006, 12, 491-505. | 2.0 | 165 |
| 5 | FDA Drug Approval Summaries: Oxaliplatin. Oncologist, 2004, 9, 8-12. | 1.9 | 150 |
| 6 | Paediatric drug development: The impact of evolving regulations. Advanced Drug Delivery Reviews, 2014, 73, 2-13. | 6.6 | 124 |
| 7 | New Models for Large Prospective Studies: Is There a Better Way?. American Journal of Epidemiology, 2012, 175, 859-866. | 1.6 | 110 |
| 8 | A constitutive damage-specific DNA-binding protein is synthesized at higher levels in UV-irradiated primate cells Molecular and Cellular Biology, 1990, 10, 2041-2048. | 1.1 | 95 |
| 9 | Developmental and tissue-specific expression of nuclear proteins that bind the regulatory element of the major histocompatibility complex class I gene Journal of Experimental Medicine, 1989, 169, 1309-1321. | 4.2 | 93 |
| 10 | Improving the value of clinical research through the use of Common Data Elements. Clinical Trials, 2016, 13, 671-676. | 0.7 | 93 |
| 11 | Drug Approval Summaries: Arsenic Trioxide, Tamoxifen Citrate, Anastrazole, Paclitaxel, Bexarotene. Oncologist, 2001, 6, 4-11. | 1.9 | 86 |
| 12 | Accelerated Approval of Cancer Drugs: Improved Access to Therapeutic Breakthroughs or Early Release of Unsafe and Ineffective Drugs?. Journal of Clinical Oncology, 2009, 27, 4398-4405. | 0.8 | 81 |
| 13 | Inhibition of estrogen-responsive gene activation by the retinoid X receptor beta: evidence for multiple inhibitory pathways Molecular and Cellular Biology, 1993, 13, 2258-2268. | 1.1 | 79 |
| 14 | Global alignment of immunization safety assessment in pregnancy – The GAIA project. Vaccine, 2016, 34, 5993-5997. | 1.7 | 72 |
| 15 | Clinical study of an organic arsenical, melarsoprol, in patients with advanced leukemia. Cancer Chemotherapy and Pharmacology, 1999, 44, 417-421. | 1.1 | 49 |
| 16 | Guideline for collection, analysis and presentation of safety data in clinical trials of vaccines in pregnant women. Vaccine, 2016, 34, 5998-6006. | 1.7 | 42 |
| 17 | Optimized DNA extraction from neonatal dried blood spots: application in methylome profiling. BMC Biotechnology, 2014, 14, 60. | 1.7 | 41 |
| 18 | Pediatric Regulatory Initiatives. Handbook of Experimental Pharmacology, 2011, 205, 245-268. | 0.9 | 37 |

| # | Article | IF | CITATIONS |
|----|---|--------------|-----------|
| 19 | Building a Common Pediatric Research Terminology for Accelerating Child Health Research. Pediatrics, 2014, 133, 516-525. | 1.0 | 35 |
| 20 | Thyroid abnormalities in children infected with human immunodeficiency virus. Journal of Pediatrics, 1996, 128, 70-74. | 0.9 | 34 |
| 21 | H-2RIIBP expressed from a baculovirus vector binds to multiple hormone response elements Molecular Endocrinology, 1992, 6, 219-230. | 3.7 | 32 |
| 22 | Oncology drug development: United States Food and Drug Administration perspective. Critical Reviews in Oncology/Hematology, 2002, 42, 137-143. | 2.0 | 30 |
| 23 | A Federated Model of IRB Review for Multisite Studies: A Report on the National Children's Study Federated IRB Initiative. IRB: Ethics & Human Research, 2014, 36, 1-6. | 0.8 | 26 |
| 24 | Use of Human Recombinant Growth Hormone and Human Recombinant Insulin-Like Growth Factor-l in Patients with Human Immunodeficiency Virus Infection. Hormone Research, 1996, 46, 215-221. | 1.8 | 24 |
| 25 | Meeting the Demand for Pediatric Clinical Trials. Science Translational Medicine, 2014, 6, 227fs11. | 5 . 8 | 23 |
| 26 | Inhibition of Estrogen-Responsive Gene Activation by the Retinoid X Receptor \hat{l}^2 : Evidence for Multiple Inhibitory Pathways. Molecular and Cellular Biology, 1993, 13, 2258-2268. | 1.1 | 23 |
| 27 | The National Children's Study â€" A Proposed Plan. New England Journal of Medicine, 2013, 369, 1873-1875. | 13.9 | 22 |
| 28 | Immunization in pregnancy clinical research in low- and middle-income countries – Study design, regulatory and safety considerations. Vaccine, 2017, 35, 6575-6581. | 1.7 | 22 |
| 29 | Challenges in clinical trials for children and young people. Archives of Disease in Childhood, 2021, 106, 321-325. | 1.0 | 21 |
| 30 | National Children's Study: Update in 2010. Mount Sinai Journal of Medicine, 2011, 78, 119-125. | 1.9 | 20 |
| 31 | Development of a Pediatric Adverse Events Terminology. Pediatrics, 2017, 139, . | 1.0 | 20 |
| 32 | Arm Span and Ulnar Length Are Reliable and Accurate Estimates of Recumbent Length and Height in a Multiethnic Population of Infants and Children under 6 Years of Age. Journal of Nutrition, 2014, 144, 1480-1487. | 1.3 | 19 |
| 33 | Longer breastfeeding duration reduces the positive relationships among gestational weight gain, birth weight and childhood anthropometrics. Journal of Epidemiology and Community Health, 2015, 69, 632-638. | 2.0 | 18 |
| 34 | Expression of major histocompatibility complex (MHC) class I genes in astrocytes correlates with the presence of nuclear factors that bind to constitutive and inducible enahcers. Journal of Neuroimmunology, 1992, 41, 35-42. | 1.1 | 16 |
| 35 | The National Children's Study: An Opportunity for Medical Toxicology. Journal of Medical Toxicology, 2012, 8, 160-165. | 0.8 | 16 |
| 36 | Dysregulation of Growth and Development in HIV-Infected Children. Journal of Nutrition, 1996, 126, 2641S-2650S. | 1.3 | 13 |

| # | Article | IF | Citations |
|----|--|-----|-----------|
| 37 | Pain as a Complication of HIV Disease. AIDS Patient Care and STDs, 1998, 12, 91-108. | 1.1 | 13 |
| 38 | Pediatric Oncology: Regulatory Initiatives. Oncologist, 2000, 5, 441-444. | 1.9 | 12 |
| 39 | Investigational new drugs submitted to the Food and Drug Administration that are placed on clinical hold: the experience of the Office of Cellular, Tissue and Gene Therapy. Cytotherapy, 2008, 10, 312-316. | 0.3 | 11 |
| 40 | Progression-free survival as an end-point in clinical trials of biotherapeutic agents. European Journal of Cancer, Supplement, 2007, 5, 23-28. | 2.2 | 10 |
| 41 | HIV-1 infected monozygotic twins: a tale of two outcomes. BMC Evolutionary Biology, 2011, 11, 62. | 3.2 | 10 |
| 42 | DEVELOPMENTAL THERAPEUTICS IN CHILDHOOD CANCER. Hematology/Oncology Clinics of North America, 2001, 15, 631-655. | 0.9 | 9 |
| 43 | Harmonizing Biomarker Measurements in Longitudinal Studies of Childrenâ \in ^{\mathbb{M}} s Health and the Environment. Biomonitoring, 2014, 1, . | 1.0 | 9 |
| 44 | Growth as a part of the composite endpoint in paediatric antiretroviral clinical trials. Journal of Antimicrobial Chemotherapy, 2004, 54, 701-703. | 1.3 | 7 |
| 45 | Introduction and Goals for the National Children's Study. Frontiers in Pediatrics, 2018, 5, 240. | 0.9 | 7 |
| 46 | Current Status of the National Children's Study. Epidemiology, 2010, 21, 605-606. | 1.2 | 5 |
| 47 | Frameworks for Evaluating Medicines in Children. Clinical Therapeutics, 2017, 39, 1949-1958. | 1.1 | 5 |
| 48 | Assessment of a shortened informed consent form for pediatric research: a pilot study. Pediatric Research, 2018, 84, 516-519. | 1.1 | 5 |
| 49 | Pediatric Patients and Drug Safety. Journal of Pediatric Hematology/Oncology, 2005, 27, 122-124. | 0.3 | 4 |
| 50 | History of Children and the Development of Regulations at the FDA. , 0, , 6-15. | | 4 |
| 51 | Prerequisites to support high-quality clinical trials in children and young people. Archives of Disease in Childhood, 2021, 106, 423-428. | 1.0 | 4 |
| 52 | Working Group Session Report: Cancer. Journal of Nutrition, 1999, 129, 306S-307S. | 1.3 | 3 |
| 53 | The FDA and The Lancet : an exchange. Lancet, The, 2001, 358, 415. | 6.3 | 3 |
| 54 | The pediatric research equity act and oncology. Pediatric Blood and Cancer, 2004, 43, 99-102. | 0.8 | 3 |

| # | Article | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Sponsors meet scientists to speed pediatric medicines development. Science Translational Medicine, 2015, 7, 279fs11. | 5.8 | 3 |
| 56 | What Could the Future of Safety Monitoring Look Like?. Therapeutic Innovation and Regulatory Science, 2019, 53, 590-600. | 0.8 | 3 |
| 57 | Health Measurement Model—Bringing a Life Course Perspective to Health Measurement: The PRISM Model. Frontiers in Pediatrics, 2021, 9, 605932. | 0.9 | 3 |
| 58 | Principles of Researching Health Disparities in Longitudinal Cohort Studies Enrolling Children. Frontiers in Pediatrics, 2021, 9, 627298. | 0.9 | 3 |
| 59 | Selected issues in human immunodeficiency virus infection in adolescents. Current Opinion in Pediatrics, 1992, 4, 599-606. | 1.0 | 2 |
| 60 | Predictive Models for Characterizing Disparities in Exclusive Breastfeeding Performance in a Multi-ethnic Population in the US. Maternal and Child Health Journal, 2016, 20, 398-407. | 0.7 | 2 |
| 61 | Weight estimation among multi-racial/ethnic infants and children aged 0–5·9 years in the USA: simple tools for a critical measure. Public Health Nutrition, 2019, 22, 147-156. | 1.1 | 2 |
| 62 | Resource expectations for pediatric studies: Correlation of study type and patient number for FDA labeling. Journal of Clinical Oncology, 2008, 26, 6632-6632. | 0.8 | 2 |
| 63 | A child is a child is a child? Paediatric terminology in a health context. Developmental Medicine and Child Neurology, 2015, 57, 985-985. | 1.1 | 1 |
| 64 | Cloned Trans-Acting Factors that Bind to the Regulatory Elements of the Major Histocompatibility Complex Class I Gene., 1990,, 125-132. | | 1 |
| 65 | Threshold of Credibility: New Approach to Licensing Acute Leukemia Therapy Blood, 2004, 104, 3128-3128. | 0.6 | 1 |
| 66 | The Role of the FDA in Cancer Clinical Trials. , 2007, 132, 51-109. | | 1 |
| 67 | Dealing with Death: Visions of Those Who Left Too Soon. American Journal of Nursing, 1996, 96, 57. | 0.2 | 0 |
| 68 | Threshold of Credibility: A New Approach to Product Development for Metastatic Melanoma Therapy. Journal of Immunotherapy, 2004, 27, S55. | 1.2 | 0 |
| 69 | A survey of phase I study designs of cellular, gene therapy and antigenic products for cancer at the US Food & Drug Administration. Journal of Clinical Oncology, 2005, 23, 6035-6035. | 0.8 | 0 |
| 70 | Reframing clinical trial design and intervention development Journal of Clinical Oncology, 2016, 34, e14044-e14044. | 0.8 | 0 |